167 related articles for article (PubMed ID: 21417821)
1. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.
Bayraktar UD; Domingo GC; Schmit J; Pereira D
Leuk Lymphoma; 2011 May; 52(5):913-5. PubMed ID: 21417821
[No Abstract] [Full Text] [Related]
2. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
[TBL] [Abstract][Full Text] [Related]
3. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
4. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
Chowdhury S; Seropian S; Marks PW
Am J Hematol; 2009 Sep; 84(9):599-600. PubMed ID: 19650144
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
9. [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Hirayama Y; Terui T; Koike K; Neda H; Ishitani K; Kohda K; Kuroda H; Iyama S; Sato T; Kobune M; Takimoto R; Kato J
Rinsho Ketsueki; 2009 Aug; 50(8):663-5. PubMed ID: 19915382
[TBL] [Abstract][Full Text] [Related]
10. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
11. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
13. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
[TBL] [Abstract][Full Text] [Related]
14. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy for acute myeloid leukemia].
Nagai T
Nihon Rinsho; 2009 Oct; 67(10):1921-5. PubMed ID: 19860191
[TBL] [Abstract][Full Text] [Related]
16. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
Sakamaki H
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
[TBL] [Abstract][Full Text] [Related]
17. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
[No Abstract] [Full Text] [Related]
18. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
19. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
[No Abstract] [Full Text] [Related]
20. Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Doyen J; Italiano A; Peyrade F; Bouyer C; Thyss A
Br J Haematol; 2008 May; 141(5):744-5. PubMed ID: 18373704
[No Abstract] [Full Text] [Related]
[Next] [New Search]
